Liu C, Adamson E, Mercola D
Sidney Kimmel Cancer Center, San Diego, CA 92121, USA.
Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11831-6. doi: 10.1073/pnas.93.21.11831.
The early growth response 1 (EGR-1) gene product is a transcription factor with role in differentiation and growth. We have previously shown that expression of exogenous EGR-1 in various human tumor cells unexpectedly and markedly reduces growth and tumorigenicity and, conversely, that suppression of endogenous Egr-1 expression by antisense RNA eliminates protein expression, enhances growth, and promotes phenotypic transformation. However, the mechanism of these effects remained unknown. The promoter of human transforming growth factor beta 1 (TGF-beta 1) contains two GC-rich EGR-1 binding sites. We show that expression of EGR-1 in human HT-1080 fibrosarcoma cells uses increased secretion of biologically active TGF-beta 1 in direct proportion (rPearson = 0.96) to the amount of EGR-1 expressed and addition of recombinant human TGF-beta 1 is strongly growth-suppressive for these cells. Addition of monoclonal anti-TGF-beta 1 antibodies to EGR-1-expressing HT-1080 cells completely reverses the growth inhibitory effects of EGR-1. Reporter constructs bearing the EGR-1 binding segment of the TGF-beta 1 promoter was activated 4- to 6-fold relative to a control reporter in either HT-1080 cells that stably expressed or parental cells cotransfected with an EGR-1 expression vector. Expression of delta EGR-1, a mutant that cannot interact with the corepressors, nerve growth factor-activated factor binding proteins NAB1 and NAB2, due to deletion of the repressor domain, exhibited enhanced transactivation of 2- to 3.5-fold over that of wild-type EGR-1 showing that the reporter construct reflected the appropriate in vivo regulatory context. The EGR-1-stimulated transactivation was inhibited by expression of the Wilms tumor suppressor, a known specific DNA-binding competitor. These results indicate that EGR-1 suppresses growth of human HT-1080 fibrosarcoma cells by induction of TGF-beta 1.
早期生长反应1(EGR-1)基因产物是一种在细胞分化和生长中起作用的转录因子。我们之前已经表明,在各种人类肿瘤细胞中外源性表达EGR-1会意外且显著地降低细胞生长和致瘤性,相反,通过反义RNA抑制内源性Egr-1表达会消除蛋白质表达、增强细胞生长并促进表型转化。然而,这些效应的机制仍然未知。人类转化生长因子β1(TGF-β1)的启动子包含两个富含GC的EGR-1结合位点。我们发现,在人类HT-1080纤维肉瘤细胞中表达EGR-1会使具有生物活性的TGF-β1分泌量增加,且与EGR-1表达量成正比(皮尔逊相关系数r = 0.96),添加重组人TGF-β1对这些细胞具有强烈的生长抑制作用。向表达EGR-1的HT-1080细胞中添加单克隆抗TGF-β1抗体可完全逆转EGR-1的生长抑制作用。携带TGF-β1启动子的EGR-1结合片段的报告基因构建体在稳定表达的HT-1080细胞或与EGR-1表达载体共转染的亲本细胞中相对于对照报告基因被激活4至6倍。由于缺失阻遏结构域而无法与共阻遏物神经生长因子激活因子结合蛋白NAB1和NAB2相互作用的突变体δEGR-1的表达,其反式激活作用比野生型EGR-1增强了2至3.5倍,这表明报告基因构建体反映了体内适当的调控环境。已知的特异性DNA结合竞争物——威尔姆斯肿瘤抑制因子的表达可抑制EGR-1刺激的反式激活作用。这些结果表明,EGR-1通过诱导TGF-β1来抑制人类HT-1080纤维肉瘤细胞的生长。